<DOC>
	<DOCNO>NCT00361959</DOCNO>
	<brief_summary>This comparator study assess relative efficacy combination product fluticasone propionate/salmeterol 50/500 tiotropium bromide rate exacerbation chronic obstructive pulmonary disease ( COPD ) two year study interval .</brief_summary>
	<brief_title>SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>A Multicentre , Randomised , Double-Blind , Double Dummy , Parallel Group , 104 Week Study Compare Effect Salmeterol/Fluticasone Propionate Combination Product ( SERETIDE ) 50/500mcg Tiotropium Bromide 18 mcg Rate Exacerbations Subjects Severe Chronic Obstructive Pulmonary Disease ( COPD )</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Inclusion criterion : Established clinical history moderate severe COPD . Post bronchodilator FEV1 &lt; 50 % predict normal . FEV1 / FVC ratio &lt; 70 % . Reversibility 400mcg albuterol less equal 10 predict Visit 1 . Free exacerbation 6 week prior screen . Current former smoker smoke history = 10 packyears history COPD exacerbation . Exclusion criterion : Current asthma , eczema , atopic dermatitis and/or allergic rhinitis . Has know respiratory disorder COPD ( e.g . lung cancer , sarcoidosis , tuberculosis lung fibrosis ) . Has narrowangle glaucoma , prostatic hyperplasia obstruction neck bladder opinion investigator prevent subject enter study . Has undergone lung transplantation and/or lung volume reduction . Female nursing mother . Requires regular ( daily ) longterm oxygen therapy ( LTOT ) . Is receive betablockers ( except eye drop ) . Has serious , uncontrolled disease likely interfere study . Has receive investigational drug within 4 week prior Visit 1 . Has , opinion investigator , evidence alcohol , drug solvent abuse . Has know suspect hypersensitivity beta2agonists , inhaled corticosteroid , anticholinergic agent component formulation ( e.g . lactose milk protein ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>fluticasone propionate/salmeterol combination</keyword>
	<keyword>tiotropium</keyword>
	<keyword>SERETIDE</keyword>
	<keyword>COPD exacerbation</keyword>
</DOC>